Perlara has published the results of a drug repurposing screen built around FARS2. The logic behind this kind of project is worth stating plainly: rather than starting from a theory about which drug ought to help and testing that one guess, you test thousands of compounds that already exist and see which ones actually do something.
Yeast as a stand-in
Baker's yeast has its own version of FARS2, a gene called MSF1, doing essentially the same job. Delete both copies and then grow the yeast in conditions that force it to rely on its mitochondria for energy, and it grows badly. That poor growth is the entire point: it's a clear, measurable, repeatable signal. If a compound helps, the yeast grows better, and you can see it in a plate reader.
A good chunk of the work happened before the screen even started — confirming the gap between healthy and knockout yeast was large, and that repeated wells gave consistent answers. A screen is only as trustworthy as its setup, and this one cleared the standard quality benchmark the field uses.
8,400 compounds, and a pattern
The team then tested a library of 8,400 compounds — mostly existing drugs and well-characterised natural products. A subset of them restored growth. The interesting part is that the hits weren't scattered at random; they clustered into recognisable chemical families:
Choline-carrying lipids — including the two strongest hits, perifosine and miltefosine. Five of the top ten hits shared this feature.
Two sphingolipid analogues, fingolimod and amiselimod.
Several fatty acids, both positively and negatively charged.
Two related families of steroidal saponins — plant compounds long used in traditional Chinese medicine.
Miltefosine stands out for a practical reason. It's an approved oral drug for leishmaniasis, a parasitic infection, and it sits on the World Health Organization's List of Essential Medicines — which means a great deal is already known about how it behaves in people. It is not approved for long-term use in any condition.
When a dozen chemically related compounds all rescue growth independently, that's a far stronger signal than a single lucky hit.
The working hypothesis is about membranes rather than about the enzyme itself. These compounds shift the balance of fats inside cells. Mitochondria are wrapped in fatty membranes, and the composition of those membranes may affect how well a cell copes when mitochondrial protein production is running below full speed. That's a hypothesis, not a conclusion — a screen tells you what worked, not why.
What comes next
The plan from here is to take the top ten to fifteen hits into human cells carrying FARS2 changes, measure whether the mitochondria in those cells genuinely respire better, and then profile the fats in those mitochondria to test the membrane idea directly.
One caveat worth stating clearly: this is early laboratory work in yeast. A compound that rescues yeast growth may do nothing at all in a person, and several of the hits are serious drugs with real side effects. Nothing here is a treatment or a recommendation — decisions about any medication or supplement belong with a clinical team.
Read the full write-up, including all the data: https://perlara.substack.com/p/fars2-cure-odyssey